Rybelsus (semaglutide) is an oral medication used in combination with exercise and a healthy diet to help treat type 2 diabetes. It’s best taken on an empty stomach but isn’t known to interact ...

Novo Nordisk’s diabetes pill Rybelsus, an oral semaglutide, reduced the risk of major heart-related events by 14% in adults with Type 2 diabetes and cardiovascular disease or chronic kidney ...

The FDA has accepted Novo’s application for a label extension for Rybelsus to reduce the risk of major adverse cardiovascular events (MACE) in adults with Type 2 diabetes who also have ...

Rybelsus (semaglutide) and Ozempic (semaglutide) are prescription drugs used to treat type 2 diabetes. Rybelsus comes as an oral tablet, while Ozempic comes as an injectable liquid solution. This ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...

Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial ...

Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus. A clinical trial of Rybelsus found that it significantly reduced the ...